NHS makes 'final' offer to Vertex

David Ramsden, chief executive of the U.K.-based Cystic Fibrosis Trust, tweeted out a letter he received from NHS England that detailed what the agency said was its "final proposal" to Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) regarding reimbursement of its cystic fibrosis drugs.

NHS England confirmed the authenticity of the letter to BioCentury...